About the Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PTLA News
Dighton police chief on leave, officer suspended as they face insider trading charges
Prosecutors allege that Dupont provided information on an upcoming acquisition of another company, Portola Pharmaceuticals, Inc. to Cronin before the information was public. Cronin, prosecutors ...
All Eyes Are on Madrigal Pharmaceuticals as FDA’s Decision Draws Closer
Later this week, the U.S. Food and Drug Administration is expected to make a decision on Madrigal Pharmaceuticals’ ...
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated ...
Madrigal Pharma CFO Alex Howarth Quits, Mardi Dier Named Replacement
Dier has more than 20 years of experience in executive financial leadership roles and was the finance chief in companies like Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin ...
Madrigal Pharmaceuticals names new CFO amid growth phase
Dier's extensive background includes serving as CFO at several companies, including Portola Pharmaceuticals, Ultragenyx Pharmaceutical (NASDAQ:RARE), Inc., and Acelyrin, Inc. During her tenure at ...
MRNS Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...
ELDN Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to ...
Merrimack Pharmaceuticals Inc MACK
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated ...
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Mardi has an ...
Loading the latest forecasts...